Exubera Large Simple Trial To Evaluate Long-Term Pulmonary And Cardiovascular Safety

NCT00359801

Last updated date
Study Location
Pfizer Investigational Site
Bay Minette, Alabama, 36507-4185, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Diabetes Mellitus
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Eligible for receiving Exubera treatment based on the approved local label

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Pregnant or lactating


- Have a progressive fatal disease or a life expectancy that prohibits them from
participating in a five-year research study

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Diabetes MellitusA Clinical Trial Assessing the Impact of Inhaled Insulin on Glucose Disposition
NCT00287066
  1. Pittsburgh, Pennsylvania
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Diabetes MellitusExubera Large Simple Trial To Evaluate Long-Term Pulmonary And Cardiovascular Safety
NCT00359801
  1. Bay Minette, Alabama
  2. Fairhope, Alabama
  3. Graysville, Alabama
  4. Pell City, Alabama
  5. Phoenix, Arizona
  6. Phoenix, Arizona
  7. Phoenix, Arizona
  8. Forrest City, Arkansas
  9. Searcy, Arkansas
  10. Cudahy, California
  11. El Cajon, California
  12. Huntington Beach, California
  13. Rolling Hills Estates, California
  14. San Jose, California
  15. Santa Ana, California
  16. Westminster, California
  17. Denver, Colorado
  18. Milford, Connecticut
  19. Wilmington, Delaware
  20. Boca Raton, Florida
  21. Clearwater, Florida
  22. Debary, Florida
  23. Gainesville, Florida
  24. Green Cove Springs, Florida
  25. Hollywood, Florida
  26. Kissimmee, Florida
  27. Kissimmee, Florida
  28. Marianna, Florida
  29. Merritt Island, Florida
  30. Miami, Florida
  31. Niceville, Florida
  32. Opa Locka, Florida
  33. Orange City, Florida
  34. Ormond Beach, Florida
  35. Pembroke Pines, Florida
  36. Plantation, Florida
  37. Port Charlotte, Florida
  38. Tampa, Florida
  39. Tampa, Florida
  40. Atlanta, Georgia
  41. Atlanta, Georgia
  42. Conyers, Georgia
  43. Decatur, Georgia
  44. Warner Robins, Georgia
  45. Boise, Idaho
  46. Greenville, Illinois
  47. Libertyville, Illinois
  48. Fishers, Indiana
  49. Indianapolis, Indiana
  50. Indianapolis, Indiana
  51. Des Moines, Iowa
  52. Louisville, Kentucky
  53. Mount Sterling, Kentucky
  54. Bossier City, Louisiana
  55. Auburn, Maine
  56. Baltimore, Maryland
  57. Elkton, Maryland
  58. Glen Burnie, Maryland
  59. Wheaton, Maryland
  60. Boston, Massachusetts
  61. Plymouth, Massachusetts
  62. Ann Arbor, Michigan
  63. Battle Creek, Michigan
  64. Battle Creek, Michigan
  65. Clinton, Michigan
  66. Flint, Michigan
  67. Muskegon, Michigan
  68. Sterling Heights, Michigan
  69. Troy, Michigan
  70. Warren, Michigan
  71. Saint Cloud, Minnesota
  72. Grand Island, Nebraska
  73. Incline Village, Nevada
  74. Belleville, New Jersey
  75. Belvidere, New Jersey
  76. Glendora, New Jersey
  77. Albuquerque, New Mexico
  78. Babylon, New York
  79. Brooklyn, New York
  80. New Hartford, New York
  81. Rochester, New York
  82. Williamsville, New York
  83. Asheboro, North Carolina
  84. Charlotte, North Carolina
  85. Morehead City, North Carolina
  86. Raleigh, North Carolina
  87. Raleigh, North Carolina
  88. Shelby, North Carolina
  89. Tabor City, North Carolina
  90. Winston-Salem, North Carolina
  91. Bismarck, North Dakota
  92. Ashtabula, Ohio
  93. Canton, Ohio
  94. Cleveland, Ohio
  95. Columbus, Ohio
  96. Dayton, Ohio
  97. McConnelsville, Ohio
  98. Zanesville, Ohio
  99. Clinton, Oklahoma
  100. Bend, Oregon
  101. Broomall, Pennsylvania
  102. Dauphin, Pennsylvania
  103. Fogelsville, Pennsylvania
  104. Hanover, Pennsylvania
  105. Harrisburg, Pennsylvania
  106. Jeannette, Pennsylvania
  107. Jenkintown, Pennsylvania
  108. Jersey Shore, Pennsylvania
  109. Norristown, Pennsylvania
  110. Philadelphia, Pennsylvania
  111. Plymouth Meeting, Pennsylvania
  112. Tipton, Pennsylvania
  113. Charleston, South Carolina
  114. Florence, South Carolina
  115. Greer, South Carolina
  116. North Myrtle Beach, South Carolina
  117. Germantown, Tennessee
  118. Corpus Christi, Texas
  119. Garland, Texas
  120. Hurst, Texas
  121. Kaufman, Texas
  122. Lubbock, Texas
  123. Midland, Texas
  124. San Antonio, Texas
  125. San Marcos, Texas
  126. Stephenville, Texas
  127. Webster, Texas
  128. Layton, Utah
  129. Chesapeake, Virginia
  130. Ettrick, Virginia
  131. Burnsville, West Virginia
  132. Charleston, West Virginia
  133. Aschaffenburg,
  134. Bad Doberan,
  135. Bad Groenenbach,
  136. Bad Oeynhausen,
  137. Bad Staffelstein,
  138. Berlin,
  139. Berlin,
  140. Bonn,
  141. Chemnitz,
  142. Datteln,
  143. Dortmund,
  144. Dortmund,
  145. Eisenach,
  146. Emden,
  147. Essen,
  148. Esslingen,
  149. Falkensee,
  150. Friedberg,
  151. Fulda,
  152. Hagen,
  153. Hamburg,
  154. Hamburg,
  155. Hohenmoelsen,
  156. Jena,
  157. Koeln,
  158. Leverkusen,
  159. Mahlberg,
  160. Mannheim,
  161. Markdorf,
  162. Marl,
  163. Meissen,
  164. Muenster,
  165. Muenster,
  166. Neuwied,
  167. Nuernberg,
  168. Reinfeld,
  169. Riesa,
  170. Schluechtern,
  171. Siegen,
  172. Suhl,
  173. Villingen-Schwenningen,
  174. Wangen I. Allgaeu,
  175. Wangen,
  176. Warburg,
  177. Manati,
  178. Boras,
  179. Forshaga,
  180. Goteborg,
  181. Lilla Edet,
  182. Chesterfield, Derbyshire
  183. Ashford, Middlesex
  184. Dronfield, Sheffield
  185. Weybridge, Surrey
  186. Woking, Surrey
  187. Rugby, Warwickshire
  188. Warminster, Wiltshire
  189. Sheffield, Yorkshire
  190. Airdrie,
  191. Bath,
  192. Bath,
  193. Birmingham,
  194. Leicester,
  195. Newcastle Upon Tyne,
  196. Newcastle Upon Tyne,
  197. Westbury,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Diabetes MellitusEfficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 2 Diabetes
NCT00136916
  1. Phoenix, Arizona
  2. Tucson, Arizona
  3. Fresno, California
  4. Greenbrae, California
  5. Los Angeles, California
  6. Sacramento, California
  7. San Diego, California
  8. San Diego, California
  9. San Luis Obispo, California
  10. Tustin, California
  11. Walnut Creek, California
  12. Denver, Colorado
  13. Hamden, Connecticut
  14. Madison, Connecticut
  15. New Britain, Connecticut
  16. Waterbury, Connecticut
  17. Chiefland, Florida
  18. Clearwater, Florida
  19. Fort Myers, Florida
  20. Hollywood, Florida
  21. Miami, Florida
  22. Ocala, Florida
  23. Palm Harbor, Florida
  24. Tallahassee, Florida
  25. West Palm Beach, Florida
  26. Honolulu, Hawaii
  27. Honolulu, Hawaii
  28. Chicago, Illinois
  29. Chicago, Illinois
  30. Chicago, Illinois
  31. Springfield, Illinois
  32. Wilmette, Illinois
  33. New Orleans, Louisiana
  34. Bethesda, Maryland
  35. Boston, Massachusetts
  36. Ann Arbor, Michigan
  37. Bloomfield Hills, Michigan
  38. Plymouth, Michigan
  39. Royal Oak, Michigan
  40. Southfield, Michigan
  41. Chesterfield, Missouri
  42. St. Louis, Missouri
  43. Butte, Montana
  44. Lincoln, Nebraska
  45. Henderson, Nevada
  46. Albuquerque, New Mexico
  47. Albuquerque, New Mexico
  48. Mineola, New York
  49. New Hyde Park, New York
  50. Rochester, New York
  51. Durham, North Carolina
  52. Winston-Salem, North Carolina
  53. Mansfield, Ohio
  54. Tulsa, Oklahoma
  55. Warwick, Rhode Island
  56. Beaumont, Texas
  57. Beaumont, Texas
  58. Corpus Christi, Texas
  59. Corpus Christi, Texas
  60. Dallas, Texas
  61. Dallas, Texas
  62. Dallas, Texas
  63. Houston, Texas
  64. Irving, Texas
  65. San Antonio, Texas
  66. Burlington, Vermont
  67. Richmond, Virginia
  68. Renton, Washington
  69. Milwaukee, Wisconsin
  70. Porto Alegre, RS
  71. Sao Paulo, SP
  72. Calgary, Alberta
  73. Calgary, Alberta
  74. Red Deer, Alberta
  75. Victoria, British Columbia
  76. Winnepeg, Manitoba
  77. Winnipeg, Manitoba
  78. Halifax, Nova Scotia
  79. Halifax, Nova Scotia
  80. London, Ontario
  81. Ottawa, Ontario
  82. Toronto, Ontario
  83. Toronto, Ontario
  84. Laval, Quebec
  85. Montreal, Quebec
  86. Montreal, Quebec
  87. Saskatoon, Saskatchewan
  88. Aguas Buenas,
  89. Anasco,
  90. Cabo Rojo,
  91. San Juan,
  92. San Juan,
ALL GENDERS
35 Years+
years
MULTIPLE SITES
Diabetes MellitusThe Aim is to Estimate the Total Amount of Insulin-producing Cells in the Pancreas by MRI.
NCT00280085
  1. New Haven, Connecticut
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Exubera Large Simple Trial To Evaluate Long-Term Pulmonary And Cardiovascular Safety
Official Title  ICMJE An International, Multicenter, Large Simple Trial To Evaluate The Long-Term Pulmonary And Cardiovascular Safety Of Exubera In Patients With Diabetes Mellitus
Brief Summary The purpose of this study is to evaluate the long-term pulmonary and cardiovascular safety of Exubera in routine clinical practice.
Detailed Description Pfizer announced in October 2007 that it would stop marketing Exubera. At that time, Pfizer committed to continued marketing until it returned the licensing rights for the technology to Nektar. Following the announcement, enrollment was halted. Subjects already enrolled and receiving treatment at the time of the halt in enrollment could continue in the study in accordance with the protocol. Nektar, the company from which Pfizer licensed Exubera, announced on April 9, 2008 that it had stopped its search for a new marketing partner. Accordingly, there will be no commercial availability of Exubera. As a result, an amendment was filed on April 16, 2008 specifying that all subjects randomized to Exubera had to be transitioned to usual diabetes care, and all study subjects followed for serious adverse events for 6 months. In accordance with this amendment, study A2171069 was terminated on April 29, 2009. Neither safety nor efficacy reasons were the cause of the study termination.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Diabetes Mellitus
Intervention  ICMJE
  • Drug: Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care
    Subjects are randomized to use Exubera. Following initial use of randomized treatment, physicians and subjects are free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice). Enrolling physicians are provided with the approved local label for Exubera to guide prescribing and treatment decisions.
  • Drug: Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care
    Subjects are randomized to use usual diabetes care. Following initial use of randomized treatment, physicians and subjects are free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice).
    Other Name: Non-Exubera
Study Arms  ICMJE
  • Experimental: Exubera
    Intervention: Drug: Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care
  • Active Comparator: Usual Diabetes Care
    Intervention: Drug: Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: December 22, 2009)
1976
Original Enrollment  ICMJE
 (submitted: July 31, 2006)
5300
Actual Study Completion Date  ICMJE April 2009
Actual Primary Completion Date December 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Eligible for receiving Exubera treatment based on the approved local label

Exclusion Criteria:

  • Pregnant or lactating
  • Have a progressive fatal disease or a life expectancy that prohibits them from participating in a five-year research study
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Germany,   Puerto Rico,   Sweden,   United Kingdom,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00359801
Other Study ID Numbers  ICMJE A2171069
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date September 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP